The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey

Journal of Neural Transmission, Supplement

Volumn , Issue 60, 2000, Pages 215-225

  Andringa, G ^a   Cools, A R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CGP 3466B; DIBENZO[B,F]OXEPIN 10 YLMETHYL METHYLPROP 2 YNYL AMINE; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; BODY POSTURE; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; GAIT; LIMB MOVEMENT; MALE; MOTOR ACTIVITY; NEUROPROTECTION; NEWBORN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RATING SCALE; RHESUS MONKEY; TREMOR;

EID: 0034517763     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6301-6_14     Document Type: Conference Paper

References (29)

1. Evaluation of new treatment strategies of Parkinson's disease in animal models: The therapeutic efficacy of the dopamine D1 antagonist SKF 83959 and the neuroprotective agent CGP 3466B
2. The validity of the pre-treated, unilaterally MPTP-treated monkey as model of Parkinson's disease: A detailed behavioral analysis of the therapeutic and undesired effects of the D2 agonist LY 171555 and the D1 agonist SKF 81927
3. The predictive validity of the drug-naive bilaterally MPTP-treated monkey as model of Parkinson's disease: Effects of L-DOPA and the D1 agonist SKF 82958
4. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
5. Der L-Dopa bei der Parkinson-Akinese
6. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys
7. Reduced apoptosis after nerve growth factor and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer
8. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
9. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems
10. Neuronal sparing and behavioural effects of the antiapoptotic drug, (-)Deprenyl, following kainic acid administration
11. Intracarotid 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine administration: Biochemical and behavioural observations in a primate model of hemiparkinsonism
12. Mechanism and consequences of nerve cell death in Parkinson's disease
13. Protein isoaspartyl methyltransferase protects from Bax-induced apoptosis
14. CGP 3466B, a dibenzoxepine derivate, increases life-span in an animal model of motoneuron disease
15. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium
16. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl
17. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism
18. MPTP-induced parkinsonism in human and non-human primates clinical and experimental aspects
19. Histochemical detection of apoptosis in Parkinson's disease
20. Levodopa induced dyskinesia: Review, observations and speculation
21. Oxidative stress and neuroprotection in Parkinson's disease: Implications from studies on dopamine-induced apoptosis
22. CGP3466 prevents neuronal death in models of ischaemia and seizure in vivo
23. CGP 3466 and CGP 3466B prevent cytosine arabinoside-induced apoptosis in cultures of cerebellar neurones
24. Deprenyl increases survival of rat foetal nigral neurones in culture
25. Developing a stable bilateral model of parkinsonism in rhesus monkeys
26. Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain
27. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease
28. Neurorescuing effects of the GAPDH ligand CGP 3466B
29. Aliphatic propargylamines: Potent, selective, irreversible monoamine oxidase B inhibitors